Skip to main content

Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.

Publication ,  Journal Article
Lowery, MA; Jordan, EJ; Basturk, O; Ptashkin, RN; Zehir, A; Berger, MF; Leach, T; Herbst, B; Askan, G; Maynard, H; Glassman, D; Covington, C ...
Published in: Clin Cancer Res
October 15, 2017

Purpose: Molecular profiling in cancer has identified potential actionable drug targets that have prompted attempts to discover clinically validated biomarkers to guide therapeutic decision-making and enrollment to clinical trials. We evaluated whether comprehensive genetic analysis of patients with pancreatic adenocarcinoma is feasible within a clinically relevant timeframe and whether such analyses provide predictive and/or prognostic information along with identification of potential targets for therapy.Experimental Design: Archival or prospectively acquired FFPE samples and matched normal DNA from N = 336 patients with pancreatic cancer were analyzed using a hybridization capture-based, next-generation sequencing assay designed to perform targeted deep sequencing of all exons and selected introns of 410 key cancer-associated genes. Demographic and treatment data were prospectively collected with the goal of correlating treatment outcomes and drug response with molecular profiles.Results: The median time from protocol consent to reporting of the genomic results was 45 days with a median time from tissue delivery of 20 days. All genetic alterations identified were stratified based upon prior evidence that the mutation is a predictive biomarker of drug response using the MSKCC OncoKB classification. Three of 225 patients (1%) received a matched therapy based upon the sequencing results.Conclusions: The practical application of molecular results to guide individual patient treatment is currently limited in patients with pancreatic adenocarcinoma. Future prospective molecular profiling efforts should seek to incorporate routine germline genetic analysis and the identification of DNA profiles that predict for clinical benefit from agents that target DNA damage repair and or immunotherapy. Clin Cancer Res; 23(20); 6094-100. ©2017 AACR.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

October 15, 2017

Volume

23

Issue

20

Start / End Page

6094 / 6100

Location

United States

Related Subject Headings

  • Phenotype
  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Oncogenes
  • Neoplasm Staging
  • Male
  • Humans
  • High-Throughput Nucleotide Sequencing
  • Genomics
  • Genome-Wide Association Study
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lowery, M. A., Jordan, E. J., Basturk, O., Ptashkin, R. N., Zehir, A., Berger, M. F., … O’Reilly, E. M. (2017). Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clin Cancer Res, 23(20), 6094–6100. https://doi.org/10.1158/1078-0432.CCR-17-0899
Lowery, Maeve A., Emmet J. Jordan, Olca Basturk, Ryan N. Ptashkin, Ahmet Zehir, Michael F. Berger, Tanisha Leach, et al. “Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.Clin Cancer Res 23, no. 20 (October 15, 2017): 6094–6100. https://doi.org/10.1158/1078-0432.CCR-17-0899.
Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Zehir A, Berger MF, et al. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clin Cancer Res. 2017 Oct 15;23(20):6094–100.
Lowery, Maeve A., et al. “Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.Clin Cancer Res, vol. 23, no. 20, Oct. 2017, pp. 6094–100. Pubmed, doi:10.1158/1078-0432.CCR-17-0899.
Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Zehir A, Berger MF, Leach T, Herbst B, Askan G, Maynard H, Glassman D, Covington C, Schultz N, Abou-Alfa GK, Harding JJ, Klimstra DS, Hechtman JF, Hyman DM, Allen PJ, Jarnagin WR, Balachandran VP, Varghese AM, Schattner MA, Yu KH, Saltz LB, Solit DB, Iacobuzio-Donahue CA, Leach SD, O’Reilly EM. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clin Cancer Res. 2017 Oct 15;23(20):6094–6100.

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

October 15, 2017

Volume

23

Issue

20

Start / End Page

6094 / 6100

Location

United States

Related Subject Headings

  • Phenotype
  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Oncogenes
  • Neoplasm Staging
  • Male
  • Humans
  • High-Throughput Nucleotide Sequencing
  • Genomics
  • Genome-Wide Association Study